Endothelial JAK2 does not enhance liver lesions in mice with Budd-Chiari syndrome
- 1 May 2018
- journal article
- letter
- Published by Elsevier in Journal of Hepatology
- Vol. 68 (5) , 1086-1087
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasmsAmerican Journal of Hematology, 2016
- EASL Clinical Practice Guidelines: Vascular diseases of the liverJournal of Hepatology, 2016
- Chronic passive venous congestion drives hepatic fibrogenesis via sinusoidal thrombosis and mechanical forcesHepatology, 2014
- Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasmBlood, 2014
- Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutationBlood, 2013
- Endothelial progenitor cells are clonal and exhibit the JAK2V617F mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasmsBlood, 2011
- The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndromeBlood, 2009
- The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 casesBlood, 2008